IRIS
TASSONE, PIERFRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.250
AS - Asia 5.030
EU - Europa 2.748
SA - Sud America 1.342
AF - Africa 98
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 19
Totale 15.512
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.939
SG - Singapore 2.310
IT - Italia 1.260
CN - Cina 1.128
BR - Brasile 1.024
IN - India 589
VN - Vietnam 543
SE - Svezia 406
GB - Regno Unito 347
DE - Germania 269
CA - Canada 236
AR - Argentina 117
FI - Finlandia 102
ID - Indonesia 77
HK - Hong Kong 71
EC - Ecuador 67
NL - Olanda 56
MX - Messico 50
BD - Bangladesh 46
RU - Federazione Russa 46
FR - Francia 42
RO - Romania 36
ES - Italia 35
CO - Colombia 33
UA - Ucraina 33
IQ - Iraq 32
PK - Pakistan 32
ZA - Sudafrica 29
JP - Giappone 28
PY - Paraguay 28
CL - Cile 25
JO - Giordania 25
EU - Europa 22
PL - Polonia 22
TR - Turchia 22
IR - Iran 20
PE - Perù 20
SA - Arabia Saudita 20
EG - Egitto 19
VE - Venezuela 18
CZ - Repubblica Ceca 17
LT - Lituania 16
AT - Austria 14
AE - Emirati Arabi Uniti 13
AU - Australia 12
MA - Marocco 12
KR - Corea 10
PT - Portogallo 9
TN - Tunisia 9
UY - Uruguay 8
ET - Etiopia 7
IE - Irlanda 7
MY - Malesia 7
NG - Nigeria 7
UZ - Uzbekistan 7
BG - Bulgaria 6
DZ - Algeria 6
EE - Estonia 6
GT - Guatemala 6
LB - Libano 6
CY - Cipro 5
HN - Honduras 5
CH - Svizzera 4
DO - Repubblica Dominicana 4
IL - Israele 4
KE - Kenya 4
KZ - Kazakistan 4
NZ - Nuova Zelanda 4
PH - Filippine 4
PS - Palestinian Territory 4
TW - Taiwan 4
AZ - Azerbaigian 3
BN - Brunei Darussalam 3
HU - Ungheria 3
LK - Sri Lanka 3
NP - Nepal 3
PA - Panama 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
GR - Grecia 2
HR - Croazia 2
KI - Kiribati 2
KW - Kuwait 2
OM - Oman 2
SN - Senegal 2
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
CV - Capo Verde 1
DK - Danimarca 1
GE - Georgia 1
GM - Gambi 1
GY - Guiana 1
JM - Giamaica 1
NI - Nicaragua 1
NR - Nauru 1
PR - Porto Rico 1
Totale 15.507
Salva come PNG Salva come JPEG
Città #
Chandler 906
Singapore 767
Dallas 505
Santa Clara 457
Bengaluru 428
Hefei 428
Milan 390
Lawrence 383
Princeton 383
Chicago 269
London 249
Ashburn 243
Wilmington 224
Ho Chi Minh City 219
Munich 209
Beijing 187
Ottawa 165
Catanzaro 153
Des Moines 111
Hanoi 102
Boardman 85
São Paulo 85
Turku 73
Los Angeles 69
Hong Kong 59
New York 54
Shanghai 48
Rome 47
Guangzhou 41
Rio de Janeiro 41
Pune 40
Naples 35
Norwalk 32
San Francisco 31
The Dalles 31
Brooklyn 30
Redwood City 30
Helsinki 29
Redmond 28
Council Bluffs 26
Montreal 22
Quito 22
Biên Hòa 21
Da Nang 21
Chennai 20
Warsaw 20
Columbus 19
Curitiba 19
Haiphong 19
Parma 19
Boston 18
Stockholm 18
Thái Bình 18
Amman 17
Salvador 17
Manchester 16
Phoenix 16
San Nicola Manfredi 16
Tokyo 16
Atlanta 15
Denver 15
Guayaquil 15
Charlotte 14
Olomouc 14
Porto Alegre 14
Reggio Calabria 14
West Jordan 14
Campinas 13
Horia 13
Mexico City 13
Mountain View 13
Amsterdam 12
Baghdad 12
Brasília 12
Buenos Aires 12
Carbonia 12
Delhi 12
Palermo 12
Recife 12
Timisoara 12
Vallefiorita 12
Washington 12
Augusta 11
Cosenza 11
Dhaka 11
Hanover 11
Johannesburg 11
Thái Nguyên 11
Bari 10
Duque de Caxias 10
Guarulhos 10
Jakarta 10
Lima 10
Madrid 10
Seattle 10
Zhengzhou 10
Ankara 9
Aversa 9
Belo Horizonte 9
Bogotá 9
Totale 8.527
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 405
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 114
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 95
miR-22 suppresses DNA ligase III addiction in multiple myeloma 95
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 84
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 80
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 78
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 77
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 71
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 68
A 5 ' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells 68
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 68
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer 68
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 68
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 67
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 67
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 67
277 POSTER An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 66
Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43 66
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 66
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 65
Pyrrolo[2′,3′:3,4]cyclohepta[1,2- d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types 65
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 64
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 63
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 63
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 62
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 61
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 61
Associazione di antagonisti di IL-6 e farmaci anti-proliferativi (depositato il 10.3.2005 n. RM2005A000103) 61
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 60
Differential microRNAs expression profile in coronary thrombi from patients with no-reflow after primary PCI 58
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 58
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 58
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 57
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 57
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 57
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 57
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 57
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 57
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 57
Fetal ontogeny and tumor expression of the early thymic antigen UN1 56
A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells 56
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 56
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 55
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 55
miR-221/222 inhibitors for the treatment of multiple myeloma 55
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 55
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 55
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 55
Mir-34: a new weapon against cancer? 53
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 53
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 53
Liposomes containing zoledronic acid: A new opportunity against cancer 53
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 53
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells (CO-FIRST AUTHOR) 53
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 52
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 52
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 52
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 52
Anti-myeloma activity of miR-125 mimics 52
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 51
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 51
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 51
Biochemical modification of an Interleukin-6 antagonist to target myeloma cells in the bone marrow microenvironment 51
HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells 51
PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle 51
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 51
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 51
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 50
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 50
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 49
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 48
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 48
Modulation of Exosomal microRNA in patients with severe Aortic Stenosis after Transcatheter Aortic Valve Implantation (TAVI) 48
Genes specifically expressed during early stages of haemopoietic differentiation detected by DDRT-PCR. 48
Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma 48
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 48
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 48
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 48
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 48
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 48
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 47
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 47
Mir-221/222 are promising targets for innovative anticancer therapy 47
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 47
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 47
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia 47
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 47
Transcriptional regulation of the mismatch repair gene hMLH1 47
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy 47
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 47
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 47
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 47
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates 47
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 47
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 46
[Extended subcutaneous mastectomy. A new type of operation in non-destructive surgery of breast neoplasms]. FT La mastectomia sottocutanea allargata. Un nuovo tipo d'intervento nella chirurgia non demolitiva della neoplasia mammaria. 46
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 46
In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma 46
Editorial: New approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta) 46
Totale 6.037
Salva come PNG Salva come JPEG
Categoria #
all - tutte 178.535
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 178.535
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021410 0 0 0 0 63 53 33 26 73 82 65 15
2021/20221.151 27 6 17 333 87 20 29 249 114 97 149 23
2022/20232.838 787 108 110 204 299 234 23 198 425 171 228 51
2023/20241.557 347 158 127 110 104 379 45 61 13 51 65 97
2024/20254.484 615 274 203 134 251 564 126 163 510 266 448 930
2025/20264.947 454 966 1.028 1.709 790 0 0 0 0 0 0 0
Totale 15.843